Investor Presentation Q1-Q3 2020

77 Investor presentation First nine months of 2020 The medium-term growth is expected to be 6-10% annually driven by securing the base and three future growth enablers Sales have increased by 5% since 2013, while medium-term growth is expected to be 6-10% 5% 6-10% ILLUSTRATIVE 2013 2014 2015 2016 2017 2018 2025 Future growth drivers Base sales with mature therapy areas Novo NordiskⓇ Secure the sales base by leveraging biopharm and portfolio of short-acting and premix insulin Drive additional growth through three future growth enablers Establish basal market leadership Ро Drive GLP-1 market growth Expand the obesity market

View entire presentation